ClinicalTrials.gg
CompletedNCT05467995Updated Mar 6, 2024

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

A Phase 2 interventional study of AK111 and Placebo in Ankylosing Spondylitis, sponsored by Akeso. Completed at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jun 2021, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Enrollment
36th of 62
125 · median 150
Started
2021
with 7 others
Phase 2
11 of 76
none open now
Registered
44th of 76
by date
Lead sponsor
2 of 76
Akeso

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 36th largest by enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2021, is one of 11 in phase 2, and was the 44th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AK111 in subjects with active ankylosing spondylitis.

Read the detailed description

The purpose of this study is to evaluate the efficacy and safety of AK111 in the treatment of subjects with active ankylosing spondylitis. Subjects will be randomized to receive AK111 or placebo following subcutaneous injection. The study period for each subject will be 25 weeks, including a screening period of up to 35 days, followed by a treatment period of 12 weeks and a follow up period of 8 weeks.

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • AK111
  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18-75 years old.
  • Ankylosing spondylitis has been diagnosed for at least 6 months before screening, with radiological evidence that meets the Modified New York Criteria for Ankylosing Spondylitis.
  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Spinal pain score≥ 4 (based on BASDAI question 2).
  • Subjects received at least 1 kind of non-steroidal anti-inflammatory drugs (NSAIDs), prior to randomization with an inadequate response or failure to respond.
  • Subjects who are regularly taking NSAIDs, weak opioids or oral as part of their AS therapy are required to be on a stable dose for at least 14 days before randomization.
  • Subjects taking methotrexate (MTX) (≤25mg/week) or Sulfasalazine (≤3g/day) are allowed to continue their medication if started at least 12 weeks prior to Baseline, with a stable dose for at least 4 weeks before randomization.

Exclusion criteria

Exclusion Criteria:

  • Subjects with total ankylosis of the spine.
  • Subjects with progressive or uncontrolled diseases of respiratory, circulatory, digestive, urogenital, endocrine, nervous or mental systems, or with other chronic diseases that are not suitable to participate to the study.
  • Subjects with other inflammatory diseases or diseases except Ankylosing spondylitis (AS).
  • Subjects with any severe systemic or local infection within 2 months before screening.
  • Subjects who are using strong opioid analgesics.
  • Combined use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) other than methotrexate and sulfasalazine, including but not limited to thalidomide, iguratimod, etc. within 4 weeks before randomization.
  • Received any within 2 months before screening or planned to receive any live vaccine during the study period.
  • Previous exposure to secukinumab, ixekizumab or any other biologic drug directly targeting IL-17 or IL-17 receptor.
  • Received Natalizumab or other drugs that regulate B cells or T cells within 6 months before screening.
  • Received more than 2 kinds of Tumor necrosis factor alpha(TNF-α) inhibitors before screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    AK111 75mg

    AK111 75mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.

    Biological: AK111

  • Experimental
    AK111 150mg

    AK111 150mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.

    Biological: AK111

  • Experimental
    AK111 300mg

    AK111 300mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.

    Biological: AK111

  • Placebo comparator
    Placebo

    Placebo will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.

    Biological: Placebo

Interventions

  • BiologicalAK111

    AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks

  • BiologicalPlacebo

    Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who achieve Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response at Week 16.

    ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global, pain, function (assessed by BASFI) and inflammation (mean of Ankylosing Spondylitis Disease Activity Index \[BASDAI\] question 5 and 6 ). ASAS20 response is defined as improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≥1 unit in the remaining domain.

    Time frame: Week16

  2. Percentage of subjects with treatment-emergent adverse events (TEAEs) during the study.

    Time frame: Baseline to Week20

  3. Percentage of subjects with treatment-emergent serious adverse events (SAEs) during the study.

    Time frame: Baseline to Week20

Secondary outcomes

  1. Percentage of subjects who achieve SpondyloArthritis International Society 40% improvement (ASAS40) response at Week 16.

    ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global, pain, function (assessed by BASFI) and inflammation (mean of Ankylosing Spondylitis Disease Activity Index \[BASDAI\] question 5 and 6 ). ASAS40 response is defined as improvement of ≥40% and ≥2 units in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening in the remaining domain.

    Time frame: Week 16

  2. Percentage of subjects who achieve ASAS20 response at each visit from baseline.

    ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global, pain, function (assessed by BASFI) and inflammation (mean of Ankylosing Spondylitis Disease Activity Index \[BASDAI\] question 5 and 6 ). ASAS20 response is defined as improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≥1 unit in the remaining domain.

    Time frame: Baseline to Week 20

  3. Percentage of subjects who achieve ASAS40 at each visit from baseline.

    ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global, pain, function (assessed by BASFI) and inflammation (mean of Ankylosing Spondylitis Disease Activity Index \[BASDAI\] question 5 and 6 ). ASAS40 response is defined as improvement of ≥40% and ≥2 units in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening in the remaining domain.

    Time frame: Baseline to Week 20

  4. Change from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at each visit from baseline.

    The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) . The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

    Time frame: Baseline to Week 20

  5. pharmacodynamics(PD) parameters: Changes of Interleukin-17A (IL-17A) level in peripheral serum compared with baseline and its relationship with AK111 exposure.

    Time frame: Baseline to Week 20

  6. Immunogenicity: Number and percentage of subjects with detectable anti-AK111 antibody (ADA).

    Time frame: Baseline to Week 20

  7. Change from baseline on the 36-item Short-Form (SF-36) Health Survey at each visit from baseline.

    The SF-36 is a 36-item generic health status measure. It measures 8 general health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health. Each of the 8 domain scores and the component summary scores range from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline to Week 20

  8. Area under the curve from 0 to the time of the last quantifiable concentration (AUC0-t)

    Time frame: Baseline to Week 20

  9. Maximum observed concentration (Cmax)

    Time frame: Baseline to Week 20

  10. Terminal elimination half-life (T1/2)

    Time frame: Baseline to Week 20

  11. Time of occurrence of Cmax (Tmax)

    Time frame: Baseline to Week 20

07

Study locations

15 sites
  • The first affiliated hospital of Bengbu medical college
    Bengbu, Anhui, China
  • Peking university people's hospital
    Beijing, Beijing, China
  • Peking University Shougang hospital
    Beijing, Beijing, China
  • Peking University Third Hospital
    Beijing, Beijing, China
  • Xuanwu hospital capital medical university
    Beijing, Beijing, China
  • Guangdong provincial people's hospital
    Guangzhou, Guangdong, China
  • Nanfang Hospital
    Guangzhou, Guangdong, China
  • The first affiliated hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • Nanjing Drum Tower hospital
    Nanjing, Jiangsu, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The first Bethune hospital of Jilin university
    Changchun, Jilin, China
  • Second hospital of Shanxi Medical university
    Taiyuan, Shanxi, China
  • The seventh affiliated hospital, Sun Yat-sen university
    Shenzhen, Shenzhen, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Apr 2022, 10 months.

Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Jul 21, 2022
StartActual
Jun 2, 2021
Primary completionActual
Apr 25, 2022
CompletionActual
May 19, 2022
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05467995
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jul 21, 2022
Start date
Jun 2, 2021
Primary completion
Apr 25, 2022
Completion
May 19, 2022
Last update
Mar 6, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gumokimab

Start the discussion